down arrow

Maat Pharma SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0012634822
EUR
4.16
-0.08 (-1.89%)

Dec 15

PAR

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
OSE Immunotherapeutics SA
Vétoquinol SA
Cellectis SA
Sensorion SA
Genfit SA
DBV Technologies SA
Adocia SA
MedinCell SA
Innate Pharma SA
Maat Pharma SA
PHAXIAM Therapeutics SA
Why is Maat Pharma SA ?
1
The company has declared Negative results for the last 3 consecutive quarters
  • INTEREST(HY) At EUR 0.62 MM has Grown at 142.52%
  • ROCE(HY) Lowest at -187.68%
  • OPERATING PROFIT(Q) Lowest at EUR -16.71 MM
2
Below par performance in long term as well as near term
  • Along with generating -46.33% returns in the last 1 year, the stock has also underperformed France CAC 40 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Maat Pharma SA for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Maat Pharma SA
-48.39%
-0.72
63.52%
France CAC 40
8.73%
0.52
16.76%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
45.89%
EBIT Growth (5y)
-214.97%
EBIT to Interest (avg)
-18.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.89
Sales to Capital Employed (avg)
0.07
Tax Ratio
10.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.67%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.60
EV to EBIT
-1.66
EV to EBITDA
-1.75
EV to Capital Employed
18.28
EV to Sales
14.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1098.83%
ROE (Latest)
-375.32%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Here's what is working for Maat Pharma SA
Inventory Turnover Ratio
Highest at 23.17%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio
Highest at 0.52%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Maat Pharma SA
Interest
At EUR 0.62 MM has Grown at 142.52%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (EUR MM)

Operating Profit
Lowest at EUR -16.71 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite negative

Operating Profit (EUR MM)

Pre-Tax Profit
Lowest at EUR -17.95 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (EUR MM)

Net Profit
Lowest at EUR -16.05 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (EUR MM)

EPS
Lowest at EUR -1.15
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (EUR)

Cash and Eqv
Lowest at EUR 20.15 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at -40.61 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 113% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."